University of Rome Tor Vergata, Department of Systems Medicine, Unit of Respiratory Clinical Pharmacology , Via Montpellier 1, Rome 00133 , Italy
Expert Opin Pharmacother. 2014 Dec;15(17):2475-8. doi: 10.1517/14656566.2014.972367. Epub 2014 Oct 18.
A growing body of evidence suggests that triple therapy with an antimuscarinic agent, a long-acting β2-agonist, and an inhaled corticosteroid is efficacious in patients with more severe chronic obstructive pulmonary disease (COPD), such as those with frequent exacerbations. Moreover, this therapy is often prescribed in real-life management of COPD, even in patients who are not suffering from severe COPD. All this makes triple therapy an attractive therapeutic approach. Therefore, a variety of triple combinations are currently under development. However, there are a number of issues that need to be addressed in order to optimize the use of triple therapy in COPD because data are still too scarce and studies too short to generate a strong recommendation.
越来越多的证据表明，在慢性阻塞性肺疾病（COPD）较为严重的患者中，三联疗法（抗毒蕈碱药物、长效β2-激动剂和吸入性皮质类固醇）具有疗效，例如那些经常发生恶化的患者。此外，这种治疗方法在 COPD 的实际管理中经常被开处，即使是在那些没有患严重 COPD 的患者中。所有这些使得三联疗法成为一种有吸引力的治疗方法。因此，目前正在开发各种三联组合。然而，为了优化 COPD 中三联疗法的使用，还需要解决一些问题，因为数据仍然太少，研究时间太短，无法产生强烈的推荐。
